the NIH Pediatric & Wildtype GIST Clinic

Fernanda I. Arnaldez, MD

Associate Research Physician – Senior Investigator

CTEP/DCTD/NCI

NIH NATIONAL CANCER INSTITUTE

July 26, 2018

DISCLOSURES

No financial relationships of commercial interest

OBJECTIVES

1. Overview of NIH Pediatric and Wild-Type GIST Clinic

2. Overview of findings and contributions

3. Highlights

4. Future Considerations

Gastrointestinal Stromal Tumors: GIST

- Most common mesenchymal neoplasms of the gastrointestinal track; but fewer than 1% all GI tumors
- Originates in the Interstitial Cells of Cajal (smooth muscle pacemakers)
- Introduced as a diagnostic term in 1983
- KIT mutations described in 1998



PRESENTATION:

Anemia
Pain
Obstruction
Fatigue
Early Satiety
Incidental Finding

GIST

Stomach



Small Bowel



www.endoskopiebilder.de

Gastrointestinal Stromal Tumors: GIST

Epithelioid



Spindle cell



Gastrointestinal Stromal Tumors: GIST

85%: mutations in KIT
10%: mutations in PGDFRA
→ SURGERY, TKIs

5%: "other"

wildtype, young patients…

Once upon a time…

- The NIH Pediatric and Wild-Type Clinic was established in 2008

the NIH Pediatric & Wildtype GIST Clinic

Established 2008

Our Clinic

Multidisciplinary

Pediatric Oncologists, Medical Oncologists, Pediatric Surgeons, Geneticists, Endocrinologists, Genetic Counsellor, Pathologists, Radiologists, Psychologists, Behavioral Therapists, Nurses, Nurse Practitioners, Nutritionists, Dermatologists, Pain Specialists, Care Coordinators…

Multi-Institutional

National Cancer Institute / Clinical Center / NICHD, Dana Farber Cancer Institute / Boston Children's Hospital, Fox Chase Cancer Center, St. Jude Children's Research Hospital, Memorial Sloan Kettering Cancer Center, Huntsman Cancer Institute, Children's Hospital Los Angeles, Sylvester Comprehensive Cancer Center, and others...

Embraced a Collaborative Model

Within and across specialists, institutions and community organizations

Reached out to patients, physicians and advocates

Findings

The vast majority (84%) of the “wild-type” GISTs are **SDH deficient**

- 75% SDH mutations
- 25% SDHC promoter hypermethylation

Other molecular features are **“rare”** but increasingly being described: NF1, BRAF, ARID1A, ARID1B, CBL, PIK3CA, HRAS, NRAS, KRAS, FGFR1, MAX, MEN1, fusions (ETV6-NTRK and others)

Often an indolent disease: **most patients survive with disease progression**. No improvement seen with extensive surgical resections. Intractable pain, obstruction and bleeding remain considerations for surgical intervention.

This approach to improve outcomes in rare diseases works…!

Frequency of SDHB-negative and SDHB-positive gastric GISTs as a function of age



Miettinen et. al
Am J Surg Pathol. 2011



Examples of **immunohistochemically SDHB-negative and SDHB-positive gastric GISTs.** A to D, SDHB-negative cases with staining limited to blood vessels, lymphohistiocytic infiltration, smooth muscle, or hepatocytes. C, Liver metastasis with positive hepatocytes. Note a faint cytoplasmic blush in panel D. E to H, SDHB-positive spindle cell and epithelioid GISTs with granular cytoplasmic staining of various intensities in tumor cells and vessel walls

Miettinen et. al
Am J Surg Pathol. 2011

Findings

- **Best screening tool is SDHB IHC**
- Critical importance of molecular characterization
- Most SDH mutations are **GERMLINE**
    - Implications for genetic counseling
- SDH Deficient GISTs are overwhelmingly **gastric** in location and most are **multifocal** and/or metastatic at presentation (only one small bowel SDH deficient GIST)
- Poor response to imatinib; definite responses to sunitinib and regorafanib - likely due to effects on VEGF
- Other trials (linsitinib, vandetanib) have been negative
- Guadecitabine trial ongoing

Findings

This approach to improve outcomes and improve knowledge in rare diseases works

Highlights

- Collaboration
- Genetic Testing and Counselling
- SURGICAL strategy
- Models
- Awareness

Awareness: leveraging social media platforms



Future Considerations

Mission of the NIH Pediatric and Wild-Type GIST Clinic: improving outcomes, quality of life, empowering patients and families

Consortium: how to better serve the GIST community

This model to be implemented in other rare malignancies in the context of the Moonshot® Initiative

Future clinical trials based on model-generated data: how to optimize

Fernanda.Arnaldez@nih.gov

www.cancer.gov **www.cancer.gov/espanol**

SDH Deficiency Leads to expression of multiple targets



Carney-Stratakis Syndrome :

-GIST, paragangliomas

-germline mutations in succinate dehydrogena

-AD with incomplete penetrance



Sudarshan S *et al*. (2007) *Nat Clin Pract Urol* **4:** 104–110